Pulse Biosciences (NASDAQ:PLSE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a hold rating in a report released on Saturday morning.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Mizuho set a $30.00 price objective on Pulse Biosciences in a report on Friday, February 6th. Finally, Oppenheimer reissued an “outperform” rating and set a $30.00 target price on shares of Pulse Biosciences in a research note on Friday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $30.00.

Pulse Biosciences Stock Down 5.7%

Shares of NASDAQ PLSE opened at $20.19 on Friday. The firm’s fifty day moving average is $16.47 and its 200 day moving average is $16.13. Pulse Biosciences has a 52 week low of $12.56 and a 52 week high of $26.30. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -18.69 and a beta of 1.77.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.06. The firm had revenue of ($0.09) million during the quarter, compared to the consensus estimate of $0.23 million.

Insider Activity

In other news, insider Kevin Patrick Danahy sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $23.53, for a total value of $470,600.00. Following the completion of the transaction, the insider owned 43,298 shares in the company, valued at $1,018,801.94. This trade represents a 31.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 85,000 shares of company stock valued at $1,994,400. 74.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares during the period. KLP Kapitalforvaltning AS lifted its position in Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after acquiring an additional 3,400 shares during the period. Finally, AlphaQuest LLC boosted its stake in Pulse Biosciences by 184.5% during the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after acquiring an additional 5,748 shares in the last quarter. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.